MX2018015112A - Composiciones de nanoemulsión de fármacos taxoides, y métodos para su uso para actuar sobre células cancerosas y células madre cancerosas. - Google Patents
Composiciones de nanoemulsión de fármacos taxoides, y métodos para su uso para actuar sobre células cancerosas y células madre cancerosas.Info
- Publication number
- MX2018015112A MX2018015112A MX2018015112A MX2018015112A MX2018015112A MX 2018015112 A MX2018015112 A MX 2018015112A MX 2018015112 A MX2018015112 A MX 2018015112A MX 2018015112 A MX2018015112 A MX 2018015112A MX 2018015112 A MX2018015112 A MX 2018015112A
- Authority
- MX
- Mexico
- Prior art keywords
- drug
- methods
- cancer
- cancer stem
- pufa
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 6
- 201000011510 cancer Diseases 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 5
- 239000007908 nanoemulsion Substances 0.000 title abstract 5
- 239000003814 drug Substances 0.000 title abstract 4
- 229940079593 drug Drugs 0.000 title abstract 4
- 210000004027 cell Anatomy 0.000 title abstract 3
- 210000000130 stem cell Anatomy 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000012377 drug delivery Methods 0.000 abstract 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 3
- 235000020660 omega-3 fatty acid Nutrition 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 abstract 2
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000036457 multidrug resistance Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nanotechnology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Epoxy Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662346755P | 2016-06-07 | 2016-06-07 | |
| PCT/US2017/036330 WO2017214260A1 (en) | 2016-06-07 | 2017-06-07 | Nanoemulsion compositions of taxoid drugs, and methods for the use thereof to target cancer cells and cancer stem cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018015112A true MX2018015112A (es) | 2019-09-09 |
Family
ID=60578981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018015112A MX2018015112A (es) | 2016-06-07 | 2017-06-07 | Composiciones de nanoemulsión de fármacos taxoides, y métodos para su uso para actuar sobre células cancerosas y células madre cancerosas. |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US10206875B2 (https=) |
| EP (1) | EP3463299A4 (https=) |
| JP (1) | JP7518604B2 (https=) |
| CN (2) | CN109562065A (https=) |
| AU (1) | AU2017277497B2 (https=) |
| CA (1) | CA3026412A1 (https=) |
| IL (1) | IL263504A (https=) |
| MX (1) | MX2018015112A (https=) |
| WO (1) | WO2017214260A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017214260A1 (en) * | 2016-06-07 | 2017-12-14 | Targagenix, Inc. | Nanoemulsion compositions of taxoid drugs, and methods for the use thereof to target cancer cells and cancer stem cells |
| CN112996501A (zh) * | 2017-12-20 | 2021-06-18 | 塔佳吉尼克斯公司 | 癌症中紫杉类纳米乳剂与免疫疗法的联合 |
| JP7610208B2 (ja) * | 2019-03-22 | 2025-01-08 | インテグレイテッド ナノセラピューティクス インコーポレイテッド | 足場部分から調製した脂質結合体 |
| EP4048310A4 (en) * | 2019-10-25 | 2024-03-13 | Amgen Inc. | COMPOSITIONS AND METHODS FOR MINIMIZING PROTEIN LOSS AT LOW PROTEIN CONCENTRATIONS |
| EP4054550A4 (en) * | 2019-11-05 | 2024-01-17 | Luminus Biosciences Inc. | NANOPARTICLES WITH PRODRUGS STABILIZED BY ALBUMIN FOR THE TREATMENT OF CANCER AND OTHER DISEASES |
| CN111004195B (zh) * | 2019-12-03 | 2022-01-28 | 沈阳药科大学 | 卡巴他赛弱碱性衍生物及其制剂 |
| CN114317398B (zh) * | 2020-09-27 | 2024-03-01 | 中国科学院分子细胞科学卓越创新中心 | Gli1和EpCAM基因共同标记的肝祖细胞群及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6426367B1 (en) * | 1999-09-09 | 2002-07-30 | Efa Sciences Llc | Methods for selectively occluding blood supplies to neoplasias |
| CN1901901B (zh) * | 2003-10-30 | 2012-07-04 | 纽约州州立大学研究基金会 | 紫杉醇-脂肪酸结合物及其药物组合物 |
| US8557861B2 (en) * | 2004-09-28 | 2013-10-15 | Mast Therapeutics, Inc. | Low oil emulsion compositions for delivering taxoids and other insoluble drugs |
| US20070148194A1 (en) * | 2005-11-29 | 2007-06-28 | Amiji Mansoor M | Novel nanoemulsion formulations |
| JP5635504B2 (ja) * | 2008-07-23 | 2014-12-03 | ブハラット セルムズ アンド ヴァクシンズ リミテッド | 安定した注射可能な水中油型ドセタキセルナノエマルション |
| US20100021471A1 (en) * | 2008-07-25 | 2010-01-28 | Brookhaven Science Associates, Llc | Carbon nanotube-based drug delivery systems and methods of making same |
| US20140105829A1 (en) * | 2012-10-15 | 2014-04-17 | Nemucore Medical Innovations, Inc. | Therapeutic nanoemulsion formulation for the targeted delivery of docetaxel and methods of making and using the same |
| SG11201609352TA (en) * | 2014-06-19 | 2017-01-27 | Solural Pharma ApS | Solid oral dosage form of lipophilic compounds |
| WO2015198350A1 (en) * | 2014-06-25 | 2015-12-30 | Synergia Bio Sciences Private Limited | A pharmaceutical oil-in-water nano-emulsion |
| WO2017214260A1 (en) * | 2016-06-07 | 2017-12-14 | Targagenix, Inc. | Nanoemulsion compositions of taxoid drugs, and methods for the use thereof to target cancer cells and cancer stem cells |
| CN112996501A (zh) * | 2017-12-20 | 2021-06-18 | 塔佳吉尼克斯公司 | 癌症中紫杉类纳米乳剂与免疫疗法的联合 |
-
2017
- 2017-06-07 WO PCT/US2017/036330 patent/WO2017214260A1/en not_active Ceased
- 2017-06-07 CN CN201780047015.5A patent/CN109562065A/zh active Pending
- 2017-06-07 CA CA3026412A patent/CA3026412A1/en active Pending
- 2017-06-07 US US15/616,103 patent/US10206875B2/en not_active Ceased
- 2017-06-07 MX MX2018015112A patent/MX2018015112A/es unknown
- 2017-06-07 AU AU2017277497A patent/AU2017277497B2/en active Active
- 2017-06-07 CN CN202310169465.9A patent/CN116019768A/zh active Pending
- 2017-06-07 JP JP2018564844A patent/JP7518604B2/ja active Active
- 2017-06-07 EP EP17810927.8A patent/EP3463299A4/en active Pending
-
2018
- 2018-12-04 IL IL263504A patent/IL263504A/en unknown
-
2021
- 2021-02-19 US US17/179,720 patent/USRE50096E1/en active Active
-
2024
- 2024-07-16 US US18/774,363 patent/US20250009658A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US10206875B2 (en) | 2019-02-19 |
| USRE50096E1 (en) | 2024-08-27 |
| NZ748915A (en) | 2024-09-27 |
| CN109562065A (zh) | 2019-04-02 |
| AU2017277497B2 (en) | 2023-05-04 |
| JP2019523226A (ja) | 2019-08-22 |
| JP7518604B2 (ja) | 2024-07-18 |
| US20180028442A1 (en) | 2018-02-01 |
| EP3463299A1 (en) | 2019-04-10 |
| CA3026412A1 (en) | 2017-12-14 |
| IL263504A (en) | 2019-01-31 |
| AU2017277497A1 (en) | 2018-12-20 |
| WO2017214260A1 (en) | 2017-12-14 |
| EP3463299A4 (en) | 2020-01-15 |
| US20250009658A1 (en) | 2025-01-09 |
| CN116019768A (zh) | 2023-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018015112A (es) | Composiciones de nanoemulsión de fármacos taxoides, y métodos para su uso para actuar sobre células cancerosas y células madre cancerosas. | |
| MX2019003173A (es) | Terapia de combinacion con agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada. | |
| MX2021013139A (es) | Composicion farmaceutica para la prevencion y/o tratamiento de dermatitis atopica que comprende antagonista de interleucina 31 (il-31) como ingrediente activo. | |
| BR112016011169A2 (pt) | Método para a produção de células imunes ex vivo que são resistentes a um fármaco análogo de purina, célula t isolada resistente a um análogo de purina, composição farmacêutica e uso das mesmas | |
| MX390954B (es) | Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo. | |
| BR112017011536A2 (pt) | terapias de combinação | |
| BR112017006113A8 (pt) | usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits. | |
| MX2015012559A (es) | Novedosos fármacos de alta penetración y sus composiciones para el tratamiento de enfermedades de parkinson. | |
| BR112020009655A8 (pt) | Anticorpo, usos de um anticorpo e uso de uma combinação farmacêutica | |
| BR112015023481A2 (pt) | composição de lipossoma de liberação controlada de fármaco | |
| PH12018550210A1 (en) | Oral dosage form with drug composition, barrier layer and drug layer | |
| Montiel-Ruiz et al. | Synergistic interactions between the antinociceptive effect of Rhodiola rosea extract and B vitamins in the mouse formalin test | |
| WO2019126302A3 (en) | Combination taxoid nanoemulsion with immunotherapy in cancer | |
| MX2018000546A (es) | Composiciones farmaceuticas que contienen celecoxib y tramadol. | |
| TR201821157T4 (tr) | İbandroni̇k asi̇t veya bunun farmasöti̇k olarak kabul edi̇lebi̇li̇r bi̇r tuzu ve d vi̇tami̇ni̇ i̇çeren oral uygulamaya yöneli̇k kati bi̇leşi̇m. | |
| AR110800A1 (es) | MÉTODOS PARA AUMENTAR EN PLASMA SANGUÍNEO LA 2-DESOXIURIDINA (dUrd) Y LA INHIBICIÓN DE LA TIMIDILATO SINTASA | |
| MX2018001989A (es) | Formulaciones farmaceuticas. | |
| PE20210041A1 (es) | Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina | |
| WO2015063613A3 (en) | Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents | |
| RU2017112748A (ru) | Композиции онапристона пролонгированного действия и способы | |
| MX2017013643A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz. | |
| Belskaya et al. | Possibilities of the treatment of speech impairment in the acute stage of ischemic stroke using neuroprotective therapy | |
| MX2017013634A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y un polvo. | |
| MX2017013633A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas. | |
| BR112014032264A8 (pt) | Composiçâo para tratamento ou prevençâo de doenças relacionadas á permeabilidade vascular, contendo imatinibe ou um sal farmaceuticamente aceitável respectivo como ingrediente ativo |